GlassScriptPhysician profile
Katherine Benefield
NPI 1356965602
$11,724.27
in general payments reported to CMS, 2019-2025
25 companies · $3,119 in 2025
The $3,119 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,224 · 2022: $1,171 · 2023: $2,911 · 2024: $3,298 · 2025: $3,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,199 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,199.21 |
| Education | $129.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,463.06 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,124.14 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,610.25 | 2021-2025 | Stelara, Tremfya |
| Pfizer INC. | $883.87 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $835.15 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $528.89 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $520.57 | 2021-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $424.62 | 2021-2024 | Linzess |
| Ardelyx, INC. | $348.08 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $280.87 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Genzyme Corporation | $276.18 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $272.09 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $248.72 | 2021-2024 | Dificid, Zinplava |
| Madrigal Pharmaceuticals | $231.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $127.78 | 2024 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $107.30 | 2021-2024 | Zeposia |
| Amgen INC. | $99.00 | 2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $93.06 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $62.02 | 2021 | |
| Qol Medical, LLC | $59.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.45 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.19 | 2024 | Cyltezo |
| Braintree Laboratories, INC. | $21.00 | 2021 | |
| Fresenius Kabi USA, LLC | $13.36 | 2023 | Idacio |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Benefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.